Should You Buy Moderna Before Aug. 5?

Moderna's experimental flu vaccine mRNA-1010 won unanimous approval from an FDA advisory panel, setting up a regulatory decision by August 5. The stock has jumped over 100% year-to-date as the biotech approaches a critical inflection point with multiple product launches slated for 2027-2028.

The advisory panel's backing marks a significant milestone for Moderna's diversification beyond COVID-19 vaccines. The company is positioning mRNA-1010 as part of a broader pipeline rollout that could reshape its revenue base within the next three to four years.

Despite the positive momentum, a Motley Fool analyst recommends waiting for a post-approval pullback before initiating positions, arguing that the recent rally has likely priced in much of the near-term upside. The 100% gain in 2025 suggests strong investor anticipation ahead of the August 5 deadline.

The advisory panel vote itself doesn't guarantee FDA approval, though unanimous recommendations typically carry significant weight in final regulatory decisions. Moderna's success in expanding beyond its COVID franchise will depend on execution through the 2027-2028 launch window.